Xenon Pharmaceuticals Inc (XENE) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xenon Pharmaceuticals Inc   (NASDAQ: XENE)


Xenon Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Xenon Pharmaceuticals Inc's ROI in the second quarter of 2026?
Xenon Pharmaceuticals Inc recorded a cumulative net loss of $-409 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -43.55%.

Within the Healthcare sector 350 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3629 to 3676.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 28.67 % 0.52 % -24.26 % -23.15 % -12.36 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,251 1,347 591 570 641
Return On Investment (TTM) -43.55 % -48.67 % -55.05 % -45.64 % -38.1 %
XENE's Overall Ranking # 3676 # 3629 # 3418 # 3440 # 2688
Seq. Investment Change TTM 19.36 % 25.29 % -6.38 % -8.1 % -6.75 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -409 -383 -346 -306 -278

XENE Company Profile >> Back to XENE Roi Comparisons >> See Annual XENE Return On Investment



Return On Investment XENE's Ranking
Within: No.
Industry # 134
Sector # 351
Overall # 3676

Return On Investment Statistics
High Average Low
-9.33 %
-31.92 %
-63.64 %
(Jun 30 2015)   (Dec 31 2017)







Financial Statements
Xenon Pharmaceuticals Inc's II. Quarter Investments $ 1,251 Millions XENE's Balance sheet
Xenon Pharmaceuticals Inc's II. Quarter Income $ -111 Millions Quarterly XENE's Income Statement
XENE's Income by Division See XENE's Income by Division


XENE Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 591 763 938 731 558
Y / Y Investment Growth -22.45 % -18.66 % 28.17 % 31.16 % 225.46 %
Net Income in Millions -346 -234 -182 -125 -77
Y / Y Net Income Growth - - - - -
Annual Return On Investment -58.49 % -30.73 % -19.45 % -17.08 % -13.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
XENE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for XENE's Competitors
Subscribers only: Roi for Xenon Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for XENE's Customers

Other Ratios
XENE's Roa XENE's Inventory Turnover Ratio XENE's Growth Rates XENE's Dividend Statistics
XENE's Profitability Ratios XENE's Asset Turnover Ratio XENE's Dividend Growth
XENE's Roe XENE's Valuation Ratios XENE's Financial Strength Ratios XENE's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:24:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.